Mammoth Biosciences is a diagnostic technology startup leveraging CRISPR to create rapid, accurate tests for infectious diseases. Its lead product is the DETECTR platform, a CRISPR-based SARS-CoV-2 assay that has already secured Emergency Use Authorization at UCSF and is being positioned for broader commercial laboratory deployment. The company’s approach differs from conventional PCR by using CRISPR enzymes to identify viral genetic material, potentially easing current U.S. testing bottlenecks. Mammoth is also collaborating with GlaxoSmithKline to build a handheld, disposable COVID-19 test capable of delivering results in roughly 20 minutes at the point of care. With fresh support from the NIH’s Rapid Acceleration of Diagnostics (RADx) program, the startup plans to scale manufacturing of DETECTR to achieve a “multi-fold increase in testing capacity” across the United States. No revenue, user, or other financial metrics were disclosed in the article.

Total raised

$258M

Funding rounds

5

Latest round

Equity

Latest activity

Jan 2022